長鴻高科(605008.SH):籌劃購買廣西長科100%股權 股票停牌
格隆匯7月7日丨長鴻高科(605008.SH)公佈,公司正在籌劃以發行股份、可轉換公司債券及支付現金的方式購買廣西長科新材料有限公司(簡稱“廣西長科”、“標的公司”)100%股權並同時募集配套資金。經公司申請,公司股票於2025年7月8日(星期二)開市起停牌,預計停牌時間不超過10個交易日。
標的公司是一家專注於特種合成樹脂高分子材料研發、生產和銷售的高新技術企業,產品包括透明ABS、高透明MS、高腈AS、高抗衝ABS/HIPS、高光ABS/HIPS等特種樹脂產品,其中透明ABS爲中國大陸首家工業化量產本體法工藝,打破了國外對透明ABS生產工藝的壟斷,可實現進口替代。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.